Neurocrine Biosciences
NBIX
#1375
Rank
C$21.45 B
Marketcap
C$215.17
Share price
1.49%
Change (1 day)
19.69%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2025 : C$0.59 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is C$0.59 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31C$0.65 B14.93%
2023-12-31C$0.56 B59.28%
2022-12-31C$0.35 B-36.44%
2021-12-31C$0.56 B6.76%
2020-12-31C$0.52 B-18.77%
2019-12-31C$0.64 B22.29%
2018-12-31C$0.52 B13.88%
2017-12-31C$0.46 B
2009-12-31C$12.13 M-35.2%
2008-12-31C$18.72 M1162.87%
2007-12-31C$1.48 M-97.63%
2006-12-31C$62.45 M-9.7%
2005-12-31C$69.16 M-12.92%
2004-12-31C$79.42 M68.05%
2003-12-31C$47.26 M277.11%
2002-12-31C$12.53 M38.33%
2001-12-31C$9.05 M56.25%
2000-12-31C$5.79 M29.68%
1999-12-31C$4.47 M-3.07%
1998-12-31C$4.61 M101.76%
1997-12-31C$2.28 M4.31%
1996-12-31C$2.19 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Repligen
RGEN
C$0.96 B 60.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
C$12.48 B 1,988.17%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
C$0.36 M-99.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
C$59.30 B 9,822.18%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
C$95.91 B 15,946.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$84.89 B 14,103.55%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
C$0.86 B 44.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
C$25.91 M-95.66%๐Ÿ‡บ๐Ÿ‡ธ USA